Key Takeaways
- HEMA, the collaborative initiative on health technology appraisals (HTAs) involving the US, Canada and England, has announced the first topic it will explore with the aim of delivering guidance.
- The initiative will produce guidance on how non-traditional treatment benefits can be used in economic evaluations to inform HTA decisions and the understanding of value.
- The guidance could lead HTA bodies across the world to make changes to their appraisal processes.
- Novel treatment benefits include scientific spillover, the value of hope and reduced fear of contagion.
Work by the transatlantic health technology appraisal (HTA) collaboration, HEMA, is underway to develop guidance on incorporating new, non-traditional types of treatment benefits into
The guidance could eventually inform pricing and bring changes to the way HTAs are conducted
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?